Diane P Nordstrom

US Patent:

7608425, Oct 27, 2009

Filed:

Oct 24, 2007

Appl. No.:

11/877728

Inventors:

David M. Goldenberg - Mendham NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edward A. Rossi - Nutley NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12P 21/06
C12N 5/00
C12N 15/00

US Classification:

435 691, 435455, 435325

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transfection under serum-free conditions. In preferred embodiments, the cells of use are SpESF or SpESF-X cells.

US Patent:

7785880, Aug 31, 2010

Filed:

Mar 17, 2009

Appl. No.:

12/405733

Inventors:

David M. Goldenberg - Mendham NJ, US
Zhengxing Qu - Warren NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edmund A. Rossi - Woodland Park NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12N 5/00
C12N 15/00
C12P 21/00

US Classification:

435325, 435 701, 435455

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

8076140, Dec 13, 2011

Filed:

Jun 21, 2010

Appl. No.:

12/819533

Inventors:

David M. Goldenberg - Mendham NJ, US
Zhengxing Qu - Warren NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edmund A. Rossi - Woodland Park NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12N 5/10

US Classification:

435455

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

8153433, Apr 10, 2012

Filed:

Nov 2, 2011

Appl. No.:

13/287395

Inventors:

David M. Goldenberg - Mendham NJ, US
Zhengxing Qu - Warren NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edmund A. Rossi - Woodland Park NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12N 5/10

US Classification:

435455

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

8372603, Feb 12, 2013

Filed:

Mar 7, 2012

Appl. No.:

13/413871

Inventors:

David M. Goldenberg - Mendham NJ, US
Zhengxing Qu - Warren NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edmund A. Rossi - Woodland Park NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12N 5/16

US Classification:

435 701

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

8569054, Oct 29, 2013

Filed:

Jan 7, 2013

Appl. No.:

13/735244

Inventors:

Zhengxing Qu - Warren NJ, US
Chien-Hsing Chang - Downington PA, US
Edmund A. Rossi - Woodland Park NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12N 5/00
C12N 15/00

US Classification:

435325, 435 701, 435455

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

20070015250, Jan 18, 2007

Filed:

Jul 14, 2006

Appl. No.:

11/487215

Inventors:

David Goldenberg - Mendham NJ, US
Zhengxing Qu - Warren NJ, US
Chien Chang - Downingtown PA, US
Edmund Rossi - Nutley NJ, US
Jeng-Dar Yang - Bedminster NJ, US
Diane Nordstrom - Rockaway NJ, US

International Classification:

C12P 21/08
C07H 21/04
C12P 21/06
C12N 9/99
C12N 5/06
C07K 16/18

US Classification:

435069100, 435184000, 435326000, 435320100, 530387100, 536023530

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

US Patent:

20110236404, Sep 29, 2011

Filed:

Aug 18, 2009

Appl. No.:

12/542792

Inventors:

David M. Goldenberg - Mendham NJ, US
Chien-Hsing Chang - Downingtown PA, US
Edmund A. Rossi - Woodland Park NJ, US
Diane Nordstrom - Rockaway NJ, US

Assignee:

IMMUNOMEDICS, INC. - Morris Plains NJ

International Classification:

A61K 39/00
C12N 5/10
C12N 9/00
C12P 21/00
C07K 2/00
C07K 14/54
C07K 14/555
C07K 14/575
C07K 14/52
C07K 14/475
C07K 14/535
C07K 14/505
C07K 14/545
C07K 14/55
C07K 14/56
C07K 14/565
C07K 14/57
C07K 14/485
A61P 37/04

US Classification:

4241841, 435325, 435326, 435328, 435183, 5303873, 5303871, 530350, 530351, 530399, 530397

Abstract:

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transfection under serum-free conditions. In preferred embodiments, the cells of use are SpESF or SpESF-X cells.